SCHEMBL1968453

SCHEMBL1968453

CC(C)(C)OC(=O)N1CC[C@@H](N)[C@H](c2cc(Cl)cc(Cl)c2)C1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
STS P08842 5/20 0.50
PDE4B Q07343 2/20 0.42
NOTCH1 P46531 1/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
THRB P10828 1/20 0.42
DPP4 P27487 1/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GPR119 Q8TDV5 2/20 0.40
NR1D1 P20393 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12513656 1.00 STS (0.50) STSPDE4BNOTCH1MAPTKDM4E
SCHEMBL30693189 1.00 STS (0.50) STSPDE4BNOTCH1MAPTKDM4E
SCHEMBL12513593 0.88 STS (0.50) STSPDE4BMEN1KMT2ANR1D1
SCHEMBL12435415 0.88 STS (0.50) STSPDE4BMEN1KMT2ANR1D1
SCHEMBL3999857 0.85 SLC6A2 (0.47) STSPDE4BGPR119
SCHEMBL12435403 0.85 SLC6A2 (0.47) STSPDE4BGPR119
SCHEMBL12586699 0.84 MEN1 (0.47) STSPDE4BDPP4MEN1KMT2A
SCHEMBL12435411 0.83 STS (0.43) STSPDE4BMEN1KMT2AGPR119
SCHEMBL2160870 0.82 RORC (0.56) STSKDM4EGPR119
SCHEMBL19893470 0.82 RORC (0.56) STSKDM4EGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE48334-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-12-01 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
EP-2336105-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B STS 2213/4885PDE4B 3803/4885NOTCH1 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.